The prospective single-center study on the efficacy and safety of rituximab for the treatment of adult and geriatric patients with primary nephrotic syndrome. - The study on efficacy and safety of rituximab for adult and geriatric patients with nephrotic syndrome.

Start Date30 Apr 2016

Sponsor / Collaborator

Tokyo Metropolitan Geriatric Hospital

JPRN-UMIN000022157 / RecruitingIIT

Changes of renal morphology and function caused by aging - Aging alteration in kidney

Start Date30 Apr 2016

Sponsor / Collaborator

Tokyo Metropolitan Geriatric Hospital

100 Clinical Results associated with Tokyo Metropolitan Geriatric Hospital

0 Patents (Medical) associated with Tokyo Metropolitan Geriatric Hospital

1,515

Literatures (Medical) associated with Tokyo Metropolitan Geriatric Hospital

26 Feb 2024·Modern Rheumatology

Predictors of damage accrual in patients with antineutrophil cytoplasmic antibody–associated vasculitis: A nationwide prospective study

Article

Author: Hirayama, Kouichi ; Wada, Takashi ; Harigai, Masayoshi ; Sada, Ken-Ei ; Hasegawa, Midori ; Sugihara, Takahiko ; Dobashi, Hiroaki ; Amano, Koichi ; Makino, Hirofumi ; Arimura, Yoshihiro ; Atsumi, Tatsuya ; Banno, Shogo ; Yamagata, Kunihiro ; Murakawa, Yohko ; Hara, Akinori

ABSTRACTObjectivesThis study elucidated the prognosis and risk factors associated with damage accrual during long-term remission maintenance therapy for patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).MethodsWe obtained data from 120 patients registered in a nationwide prospective cohort study on remission induction therapy in Japanese patients with AAV and rapidly progressive glomerulonephritis (RemIT-JAV-RPGN), who achieved remission at 24 months after treatment initiation and were followed up for additional 24 months. The primary outcome was the vasculitis damage index (VDI) score at Month 48, and the secondary outcome included risk factors associated with increased total VDI at Month 48.ResultsThe understudied patients comprised 52 men and 68 women aged 68 ± 13 years. Between Months 25 and 48, the patients’ survival rate was 95% (114/120). End-stage renal disease developed in seven patients by Month 48, and 64 cases had increased VDI. The multivariable analysis results revealed that oral prednisolone (PSL) doses at Month 24 were associated with damage accrual between Months 24 and 48.ConclusionsVDI accrual was observed in more than half of patients with AAV during maintenance therapy, and increased VDI scores were associated with oral PSL doses 24 months after initiating remission induction therapy in Japan.

09 Dec 2023·Rheumatology Advances in Practice

Effectiveness and safety of treat-to-target strategy for methotrexate-naïve rheumatoid arthritis patients >75 years of age

Article

Author: Miyasaka, Nobuyuki ; Sugihara, Takahiko ; Hirano, Fumio ; Hosoya, Tadashi ; Ishizaki, Tatsuro ; Matsumoto, Takumi ; Kojima, Masayo ; Kubo, Kanae ; Harigai, Masayoshi ; Kamiya, Mari ; Baba, Hiroyuki ; Tsuchida, Marina

AbstractObjectivesTo identify differences in effectiveness and safety of a treat-to-target (T2T) strategy comparing late-onset MTX-naïve RA patients (LORA) ≥75 or <75 years of age.MethodsTreatment was adjusted to target low disease activity with conventional synthetic DMARDs followed by biologic DMARDs (bDMARDs) in LORA ≥75 years (n = 98, mean age 80.0 years) and LORA <75 years (n = 99) with moderate–high disease activity. Achievement of Simplified Disease Activity Index (SDAI) remission at week 156 by non-responder imputation analysis was evaluated as a primary outcome.ResultsLORA ≥75 years had more comorbidities than LORA <75 years, but SDAI and ACPA positivity were similar at baseline. Of the LORA ≥75 years, 70.4% started MTX and 34.1% and 37.1% received a bDMARD at week 52 and 156, respectively (very similar to the LORA <75 years). Glucocorticoid use was more frequent in the LORA ≥75 years than in the LORA <75 years. Comorbidities/adverse events more frequently contributed to the reasons for non-adherence to T2T in the LORA ≥75 than in the LORA <75. At week 156, 32.7% of the LORA ≥75 and 66.7% of the LORA <75 achieved SDAI remission (P < 0.001). The cumulative incidence of serious adverse events (SAEs) over 156 weeks was 42.8% in the LORA ≥75 and 22.1% in the LORA <75. Multivariable analysis indicated an increased risk of SDAI non-remission at week 156 in the LORA ≥75 [odds ratio 2.82 (95% CI 1.29. 6.14)] after adjusting for comorbidities at baseline, non-adherence to T2T and SAEs.ConclusionsIt was more difficult to achieve remission in the LORA ≥75 patients than in the LORA <75 patients due to both poor treatment response and safety issues.

01 Dec 2023·YAKUGAKU ZASSHI

Survey on the Current Advertising and Sales of <i>Mucuna pruriens</i> in Consumer-to-consumer Internet Trading in Japan

Article

Author: Niimi, Yoshiki ; Iwata, Atsushi ; Sato, Kenichiro ; Iwatsubo, Takeshi ; Hida, Ayumi

Mucuna pruriens (MP) is leguminous plant which contains 5% of L-3,4-dihydroxyphenylalanine (levodopa) in its seeds. It may have a potential to be used as an alternative therapy for Parkinson's disease (PD). Meanwhile, there is a concern in terms of public health that MP products can be overused by patients with PD. As an entry for patients with PD to acquire MP products in Japan, they are often purchased via internet auctions or free markets. MP products are not reagrded as 'pharmatheutical' by Japanese law as long as the specific legal requirements on advertisements are met, so that the MP products can be advertised or sold without any permission from the authorities. In this study, we aimed to conduct internet survey as to the complianse status of these legal requirements. Several major internet auction or free market websites in Japan were surveyed in May-June 2023 by the authors, and 1157 MP product pages were examined. We found approximately 30-40% of the MP products were suspected to have potential legal risks in terms of their advertisements in their website descriptions, such as claiming pharmatheutical efficacy or describing pharmatheutical-like dosages. In addition, approximately 30-40% of the MP products also did not refer to cautions not to take MP products excessively because of the levodopa ingredients. Current study suggested the need of careful description of the MP products in the auction or free market websites for the MP products exhibitors or sellers, in order to fullfill legal requirements as well as to prevent MP abuse.

100 Deals associated with Tokyo Metropolitan Geriatric Hospital

100 Translational Medicine associated with Tokyo Metropolitan Geriatric Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tokyo Metropolitan Geriatric Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 22 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing